Relapse and Recovery in Drug Abuse, 72
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Empirical Evidence for Definitions of Episode, Remission, Recovery, Relapse and Recurrence in Depression: a Systematic Review
Epidemiology and Psychiatric Sciences (2019), 28, 544–562. © Cambridge University Press 2018 ORIGINAL ARTICLE doi:10.1017/S2045796018000227 Empirical evidence for definitions of episode, remission, recovery, relapse and recurrence in depression: a systematic review P. L. de Zwart1*, B. F. Jeronimus1,2 and P. de Jonge1,2 1 University of Groningen, University Medical Center Groningen, Department of Psychiatry, Interdisciplinary Center Psychopathology and Emotion Regulation (ICPE), Groningen, The Netherlands 2 University of Groningen, Faculty of Behavioural and Social Sciences, Department of Developmental Psychology, Groningen, The Netherlands Aims. For the past quarter of a century, Frank et al.’s (1991) consensus-based definitions of major depressive disorder (MDD) episode, remission, recovery, relapse and recurrence have been the paramount driving forces for consistency in MDD research as well as in clinical practice. This study aims to review the evidence for the empirical validation of Frank et al.’s proposed concept definitions and to discuss evidence-based modifications. Methods. A literature search of Web of Science and PubMed from 1/1/1991 to 08/30/2017 identified all publications which referenced Frank et al.’s request for definition validation. Publications with data relevant for validation were included and checked for referencing other studies providing such data. Results. A total of 56 studies involving 39 315 subjects were included, mainly presenting data to validate the severity and duration thresholds for defining remission and recovery. Most studies indicated that the severity threshold for defining remission should decrease. Additionally, specific duration thresholds to separate remission from recovery did not add any predictive value to the notion that increased remission duration alleviates the risk of reoccurrence of depressive symp- toms. -
Impact of Disclosure of Relapse for Self-Identified Sexual Addicts
Sexual Addiction & Compulsivity, 20:157–170, 2013 Copyright © Taylor & Francis Group, LLC ISSN: 1072-0162 print / 1532-5318 online DOI: 10.1080/10720162.2013.786659 ARTICLES Impact of Disclosure of Relapse for Self-Identified Sexual Addicts M. DEBORAH CORLEY Sante´ Center for Healing, Argyle, Texas SARA E. POLLARD and JOSHUA N. HOOK University of North Texas, Denton, Texas JENNIFER P. SCHNEIDER Tucson, Arizona Disclosure as a process of both recovery and healing within commit- ted relationships is advocated by couple and addiction therapists. The traumatic impact for partners of an initial disclosure or discov- ery of betrayals has been well documented, but less is known about the impact of disclosure for sex addicts. The present study explored the experience of relapse and disclosure among sex addicts. Relapse was a common experience among sex addicts, and the disclosure of relapse had a range of consequences for the addict and the re- lationship. Voluntary disclosure of relapse (rather than the partner discovering relapses independently) was associated with positive relational outcomes. The majority of sexual behaviors engaged in by sexual addicts who are in a committed relationship are considered a violation of trust by their partners (Bird, Butler, & Fife, 2007; Kalichman & Cain, 2004; Young, Griffin-Shelley, Cooper, O’Mara, & Buchanan, 2000). This violation is also considered a betrayal and may be described as a secret sexual, romantic, or emotional involvement that violates the rules of and commitment to an exclusive re- lationship (Glass, 2002; Laaser, 2011; Whisman & Wagers, 2005). The most significant betrayals are those associated with repeated secrets, lies, decep- tions, and broken promises (Corley & Schneider, 2002; Corley, Schneider, Thanks to Dr. -
Medications to Treat Opioid Use Disorder Research Report
Research Report Revised Junio 2018 Medications to Treat Opioid Use Disorder Research Report Table of Contents Medications to Treat Opioid Use Disorder Research Report Overview How do medications to treat opioid use disorder work? How effective are medications to treat opioid use disorder? What are misconceptions about maintenance treatment? What is the treatment need versus the diversion risk for opioid use disorder treatment? What is the impact of medication for opioid use disorder treatment on HIV/HCV outcomes? How is opioid use disorder treated in the criminal justice system? Is medication to treat opioid use disorder available in the military? What treatment is available for pregnant mothers and their babies? How much does opioid treatment cost? Is naloxone accessible? References Page 1 Medications to Treat Opioid Use Disorder Research Report Discusses effective medications used to treat opioid use disorders: methadone, buprenorphine, and naltrexone. Overview An estimated 1.4 million people in the United States had a substance use disorder related to prescription opioids in 2019.1 However, only a fraction of people with prescription opioid use disorders receive tailored treatment (22 percent in 2019).1 Overdose deaths involving prescription opioids more than quadrupled from 1999 through 2016 followed by significant declines reported in both 2018 and 2019.2,3 Besides overdose, consequences of the opioid crisis include a rising incidence of infants born dependent on opioids because their mothers used these substances during pregnancy4,5 and increased spread of infectious diseases, including HIV and hepatitis C (HCV), as was seen in 2015 in southern Indiana.6 Effective prevention and treatment strategies exist for opioid misuse and use disorder but are highly underutilized across the United States. -
Alcohol Use Disorder Relapse Factors a Systematic Review
Psychiatry Research 278 (2019) 97–115 Contents lists available at ScienceDirect Psychiatry Research journal homepage: www.elsevier.com/locate/psychres Alcohol use disorder relapse factors: A systematic review T ⁎ Wilco Sliedrechta, , Ranne de Waartb, Katie Witkiewitzc, Hendrik G. Roozend a De Hoop GGZ, Provincialeweg 70, 3329 KP Dordrecht, the Netherlands b Mentrum/Arkin, Wisselwerking 46-48, 1112 XR Diemen, the Netherlands c The University of New Mexico (UNM), MSC 03-2220, Univ of New Mexico, Albuquerque, NM 87131, USA d The University of New Mexico (UNM), Center on Alcoholism, Substance Abuse, and Addictions (CASAA), MSC 11 6280, 1 Univ of New Mexico, Albuquerque, NM 87106, USA ARTICLE INFO ABSTRACT Keywords: A relapsing-remitting course is very common in patients with an Alcohol Use Disorder (AUD). Understanding the Remittance determinants associated with alcohol resumption remains a formidable task. This paper examines relapse de- Recurrence terminants based on a systematic review of recent alcohol literature (2000–2019). Relevant databases were Relapse determinants consulted for articles that contained information about specific relapse determinants and reported statistical Dual diagnosis significance of each relapse determinant in predicting relapse. Relapse was broadly defined based on the Biopsychosocial model characterization in the included articles. From the initial identified 4613 papers, a total of 321 articles were Spiritual included. Results encompass multiple relapse determinants, which were ordered according to biopsychosocial and spiritual categories, and presented, using a descriptive methodology. Psychiatric co-morbidity, AUD se- verity, craving, use of other substances, health and social factors were consistently significantly associated with AUD relapse. Conversely, supportive social network factors, self efficacy, and factors related to purpose and meaning in life, were protective against AUD relapse. -
National Vital Statistics Report: Drugs Most Frequently Involved In
National Vital Statistics Reports Volume 67, Number 9 December 12, 2018 Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2011–2016 by Holly Hedegaard, M.D., M.S.P.H., and Brigham A. Bastian, B.S., National Center for Health Statistics; James P. Trinidad, M.P.H., M.S., U.S. Food and Drug Administration; Merianne Spencer, M.P.H., and Margaret Warner, Ph.D., National Center for Health Statistics Abstract overdose deaths involving methadone decreased from 1.4 per 100,000 in 2011 to 1.1 in 2016. The 10 most frequently Objective—This report identifies the specific drugs involved mentioned drugs often were found in combination with each most frequently in drug overdose deaths in the United States other. The drugs most frequently mentioned varied by the intent from 2011 through 2016. of the drug overdose death. In 2016, the drugs most frequently Methods—Record-level data from the 2011–2016 National mentioned in unintentional drug overdose deaths were fentanyl, Vital Statistics System–Mortality files were linked to electronic heroin, and cocaine, while the drugs most frequently mentioned files containing literal text information from death certificates. in suicides by drug overdose were oxycodone, diphenhydramine, Drug overdose deaths were identified using the International hydrocodone, and alprazolam. Classification of Diseases, Tenth Revision underlying cause- Conclusions—This report identifies patterns in the specific of-death codes X40–X44, X60–X64, X85, and Y10–Y14. Drug drugs most frequently involved in drug overdose deaths from mentions were identified by searching the literal text in three 2011 through 2016 and highlights the importance of complete fields of the death certificate: the causes of death from Part I, and accurate reporting in the literal text on death certificates. -
Predicting Relapse to Alcohol and Drug Abuse Via Quantitative Electroencephalography Lance O
Predicting Relapse to Alcohol and Drug Abuse via Quantitative Electroencephalography Lance O. Bauer, Ph.D. A sensitive and specific screening test that would identify abstinence and 22 additional subjects with no history of the subset of substance-abusing patients at highest risk for substance dependence. Importantly, in subsequent logistic relapse would constitute an important advance for treatment regression analyses, fast  power was found to be superior to planning. This study examined the relative value of severity of illness, depression level, and childhood conduct quantitative electroencephalography as a rapid, inexpensive, problems in predicting relapse. With fast  power as the sole and noninvasive measure of relapse potential. The subjects predictor, the sensitivity, specificity, and positive and were 107 substance-dependent patients enrolled in negative predictive value parameters for discriminating residential treatment programs. All were unmedicated and outcomes were 0.61, 0.85, 0.75, and 0.74, respectively. free of the complicating effects of major medical and Additional ANCOVAs revealed that the EEG difference neurological disorders. Structured clinical interview data between relapse-prone and abstinence-prone groups was and a 5-minute recording of the resting, eyes-closed related to the interaction of two premorbid factors, viz., electroencephalogram were obtained after patients had childhood Conduct Disorder and paternal alcoholism. The verifiably maintained abstinence for 1–5 months. Patients enhancement of fast  electroencephalographic activity in were then monitored for relapse or successful abstinence by patients who will later relapse most likely originates from a research staff for an ensuing 6-month period. ANCOVAs of premorbid and subtle dysfunction involving frontal brain EEG power spectral density within pre-defined frequency regions. -
What Are the Treatments for Heroin Addiction?
How is heroin linked to prescription drug abuse? See page 3. from the director: Research Report Series Heroin is a highly addictive opioid drug, and its use has repercussions that extend far beyond the individual user. The medical and social consequences of drug use—such as hepatitis, HIV/AIDS, fetal effects, crime, violence, and disruptions in family, workplace, and educational environments—have a devastating impact on society and cost billions of dollars each year. Although heroin use in the general population is rather low, the numbers of people starting to use heroin have been steadily rising since 2007.1 This may be due in part to a shift from abuse of prescription pain relievers to heroin as a readily available, cheaper alternative2-5 and the misperception that highly pure heroin is safer than less pure forms because it does not need to be injected. Like many other chronic diseases, addiction can be treated. Medications HEROIN are available to treat heroin addiction while reducing drug cravings and withdrawal symptoms, improving the odds of achieving abstinence. There are now a variety of medications that can be tailored to a person’s recovery needs while taking into account co-occurring What is heroin and health conditions. Medication combined with behavioral therapy is particularly how is it used? effective, offering hope to individuals who suffer from addiction and for those around them. eroin is an illegal, highly addictive drug processed from morphine, a naturally occurring substance extracted from the seed pod of certain varieties The National Institute on Drug Abuse (NIDA) has developed this publication to Hof poppy plants. -
Adolescent Drug Terminology and Trends: 2017-18 Edition
Adolescent Drug Terminology and Trends: 2017-18 Edition Matthew Quinn, LCPC, CADC Community Relations Coordinator Vaping Term used to describe when a substance is heated to the point of releasing vapor but not combusted (lit on fire). • Increasing in popularity as a way to ingest nicotine and cannabis, often in an electronic device that looks like a pen • Usually relatively odorless and difficult to distinguish between nicotine and cannabis vape device Juul (pronounced jewel) Specific vaping product from Pax Labs similar to an e- cigarette used to ingest nicotine • Liquid contains nicotine salts extracted from the tobacco leaf (2x nicotine of previous e-cigs) • Variety of flavors • Cool mint • Mango • Crème brule Dabs Dabs is a highly concentrated butane hash oil (BHO) created in a process where high quality cannabis is blasted with butane and extracted. • Heated and inhaled • Contains 70-90% THC compared to 5-15% THC in regular cannabis • Wax, oil, shatter, crumble • Sauce, distillate Rig A rig is a device used to vaporize and inhale dabs. • Looks similar to a water pipe or bong • Usually a nail is heated with a hand- held torch to a high temperature and a small piece of the concentrate is ‘dabbed’ onto a nail • Vapor released is then inhaled through the pipe Edibles • Increasingly popular alternative to smoking marijuana • Produced to infuse marijuana into various ingestible forms • Problem is that effects are hard to predict and difficult to know dose Other Terms for Cannabis • Bud • Dank • Nug • Loud • Fire • Gas Bars (Ladders) Another name for the rectangular shaped Xanax (anti- anxiety medication) with three lines in them (typically 2mg per ‘bar’). -
Drug Fact Sheet: Oxycodone
Oxycodone WHAT IS OXYCODONE? What is its effect on the mind? Oxycodone is a semi-synthetic narcotic analgesic Euphoria and feelings of relaxation are the most and historically has been a popular drug of abuse common effects of oxycodone on the brain, which among the narcotic abusing population. explains its high potential for abuse. WHAT IS ITS ORIGIN? What is its effect on the body? Oxycodone is synthesized from thebaine, a Physiological effects of oxycodone include: constituent of the poppy plant. • Pain relief, sedation, respiratory depression, constipation, papillary constriction, and cough What are common street names? suppression. Extended or chronic use of oxycodone Common street names include: containing acetaminophen may cause severe liver • Hillbilly Heroin, Kicker, OC, Ox, Roxy, Perc, and Oxy damage What does it look like? What are its overdose effects? Oxycodone is marketed alone as OxyContin® in Overdose effects include: 10, 20, 40 and 80 mg extended-release tablets • Extreme drowsiness, muscle weakness, confusion, cold and other immediate-release capsules like 5 and clammy skin, pinpoint pupils, shallow breathing, mg OxyIR®. It is also marketed in combination slow heart rate, fainting, coma, and possible death products with aspirin such as Percodan® or acetaminophen such as Roxicet®. Which drugs cause similar effects? Drugs that cause similar effects to Oxycodone How is it abused? include: Oxycodone is abused orally or intravenously. • Opium, codeine, heroin, methadone, hydrocodone, The tablets are crushed and sniffed or dissolved fentanyl, and morphine in water and injected. Others heat a tablet that has been placed on a piece of foil then inhale the What is its legal status in the United States? vapors. -
NIDA Modified ASSIST (Pdf)
1 NIDA Quick Screen V1.0F Name: ......................................................................... Sex ( ) F ( ) M Age....... Interviewer........................................ Date ....../....../...... Introduction (Please read to patient) Hi, I’m __________, nice to meet you. If it’s okay with you, I’d like to ask you a few questions that will help me give you better medical care. The questions relate to your experience with alcohol, cigarettes, and other drugs. Some of the substances we’ll talk about are prescribed by a doctor (like pain medications). But I will only record those if you have taken them for reasons or in doses other than prescribed. I’ll also ask you about illicit or illegal drug use––but only to better diagnose and treat you. Instructions: For each substance, mark in the appropriate column. For example, if the patient has used cocaine monthly in the past year, put a mark in the “Monthly” column in the “illegal drug” row. NIDA Quick Screen Question: In the past year, how often have you used the following? Daily Twice Never Almost Almost Weekly Daily or Once or Monthly Alcohol • For men, 5 or more drinks a day • For women, 4 or more drinks a day Tobacco Products Prescription Drugs for Non-Medical Reasons Illegal Drugs . If the patient says “NO” for all drugs in the Quick Screen, reinforce abstinence. Screening is complete. If the patient says “Yes” to one or more days of heavy drinking, patient is an at-risk drinker. Please see NIAAA website “How to Help Patients Who Drink Too Much: A Clinical Approach” http://pubs.niaaa.nih.gov/publications/Practitioner/CliniciansGuide2005/clinicians_guide.htm, for information to Assess, Advise, Assist, and Arrange help for at risk drinkers or patients with alcohol use disorders . -
Getting Through Amphetamine Withdrawal – a Guide for People
Amphetamine_wdl_220404.qxd 28/04/2004 12:19 PM Page i GETTING THROUGH AMPHETAMINE WITHDRAWAL A guide for people trying to stop amphetamine use Amphetamine_wdl_220404.qxd 28/04/2004 12:19 PM Page ii GETTING THROUGH AMPHETAMINE WITHDRAWAL CONTENTS About this book x Making the decision to stop using amphetamines x Amphetamine withdrawal x What is withdrawal? x How long will the symptoms last? What kinds of symptoms will I have? x Getting started x Organise a safe environment x Organise support x Structure your day x The role of medication x Getting through withdrawal x Cravings x Sleep x September 1996 Relaxing x Revised May 2004 Mood swings x © Turning Point Alcohol and Drug Centre Inc. Strange thoughts x 54-62 Gertrude Street, Fitzroy VIC 3065 Eating again x T: 03 8413 8413 Aches and pains x F: 03 9416 3420 High-risk situations x Counselling x E: [email protected] It’s all too much x www.turningpoint.org.au Sex and withdrawal x Original edition by Dr Nik Lintzeris, Dr Adrian Dunlop and After withdrawal x David Thornton What next? x Updated (2004) by Dr Adrian Dunlop, Sandra Hocking, Dr Getting back on track if you ‘slip up’ x Nicole Lee and Peter Muhleisen Notes for supporters x Cartoonist: Mal Doreian Useful contact numbers x ISBN 0_958 6979_1_4 1 Amphetamine_wdl_220404.qxd 28/04/2004 12:19 PM Page 2 GETTING THROUGH AMPHETAMINE WITHDRAWAL MAKING THE DECISION TO STOP USING AMPHEATMINES ABOUT THIS BOOK This book is written for people who are thinking about You may find it helpful to make a list of the positives and the or trying to stop using amphetamines, even if just for a negatives about using amphetamines. -
Hallucinogens
Hallucinogens What are hallucinogens? Hallucinogens are a diverse group of drugs that alter a person’s awareness of their surroundings as well as their own thoughts and feelings. They are commonly split into two categories: classic hallucinogens (such as LSD) and dissociative drugs (such as PCP). Both types of hallucinogens can cause hallucinations, or sensations and images that seem real though they are not. Additionally, dissociative drugs can cause users to feel out of control or disconnected from their body and environment. Some hallucinogens are extracted from plants or mushrooms, and some are synthetic (human- made). Historically, people have used hallucinogens for religious or healing rituals. More recently, people report using these drugs for social or recreational purposes, including to have fun, deal with stress, have spiritual experiences, or just to feel different. Common classic hallucinogens include the following: • LSD (D-lysergic acid diethylamide) is one of the most powerful mind-altering chemicals. It is a clear or white odorless material made from lysergic acid, which is found in a fungus that grows on rye and other grains. LSD has many other street names, including acid, blotter acid, dots, and mellow yellow. • Psilocybin (4-phosphoryloxy-N,N- dimethyltryptamine) comes from certain types of mushrooms found in tropical and subtropical regions of South America, Mexico, and the United States. Some common names for Blotter sheet of LSD-soaked paper squares that users psilocybin include little smoke, magic put in their mouths. mushrooms, and shrooms. Photo by © DEA • Peyote (mescaline) is a small, spineless cactus with mescaline as its main ingredient. Peyote can also be synthetic.